Gerald Edward Archer | Scholars@Duke

Gerald Edward Archer
Assistant Professor of Neurosurgery

My current research focus involves the delivery of therapeutic agents for the treatment of central nervous system neoplasia. Utilizing athymic rat models of central nervous system neoplasia I am investigating compartmental approaches to increase therapeutic efficacy of chemotherapeutic agents and immunoconjugates. Preclinical testing in athymic rats of intrathecal administration of melphalan and 4-hydroperoxycyclophosphamide have resulted in the FDA granting investigational new drug protocols for the treatment of neoplastic meningitis using these two agents. I am also currently involved with the selective intraarterial administration of alkylator resistance modulators to treat intraparechymal brain tumors which are resistant to conventional alkylator therapy. I am also working in collaboration with Dr. Darell Bigner on the characterization of MAbs that react with the epidermal growth factor receptor variant III mutant, a tumor specific antigen.

Current Appointments & Affiliations

Assistant Professor of Neurosurgery, Neurosurgery, Neurosurgery 2021
Assistant Professor of Pathology, Pathology, Clinical Science Departments 2020

Contact Information

208 Sands, Durham, NC 27710
Box 3050 Med Ctr, Durham, NC 27710
gary.archer@duke.edu (919) 684-6977

Background
Education, Training, & Certifications
- Ph.D., University of Cincinnati 1988
Previous Appointments & Affiliations
- Assistant Professor of Neurosurgery, Neurosurgery, Neurosurgery 2006 - 2020
- Assistant Professor of Pathology, Pathology, Clinical Science Departments 2006 - 2020
- Assistant Research Professor of Pathology, Pathology, Clinical Science Departments 2000 - 2006
- Assistant Research Professor in Surgery, Neurosurgery, Neurosurgery 2001 - 2006
- Assistant Research Professor in Surgery, Surgery, Clinical Science Departments 2000 - 2001
- Assistant Research Professor of Pathology, Neurosurgery, Neurosurgery 1994 - 2000
Research
Selected Grants
- Improved monitoring of 2-Hydroxyglutarate to stage response of combined Vorasidenib and Tumor Specific Peptide Vaccine therapies in recurrent IDH1 mutant lower grade glioma awarded by National Institutes of Health 2022 - 2026
- Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma awarded by National Institutes of Health 2021 - 2025
- Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy awarded by National Institutes of Health 2018 - 2023
- Metabolic reprogramming to improve EGFRvIII CAR T cell persistence awarded by University of North Carolina - Chapel Hill 2023
- Creating the next generation peptide vaccine directed at cytomegalovirus antigens in malignant brain awarded by National Pediatric Cancer Foundation, Inc. 2022 - 2023
- Human EGFRvIII-specific BiTE for the treatment of Glioblastoma awarded by National Institutes of Health 2015 - 2023
- Efficacy of dendritic cell vaccines targeting CMV antigens in glioblastoma awarded by University of Florida 2017 - 2021
- Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma awarded by Annias Immunotherapeutics, Inc. 2015 - 2020
- Development of a Therapeutic for Brain Tumor Immunotherapy awarded by National Institutes of Health 2018 - 2019
- Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells awarded by National Institutes of Health 2013 - 2018
- Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide awarded by National Institutes of Health 2009 - 2014
- RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells awarded by National Institutes of Health 2008 - 2013
- Gene-engineered adoptive T cell immunotherapy of GBM awarded by National Institutes of Health 2012
- Src On Primary And Matastatic Tumors Of The Cns awarded by National Institutes of Health 1994 - 1999
- Src On Primary And Metastatic Tumors Of The Cns awarded by National Institutes of Health 1997 - 1999
External Relationships
- Annias Immunotherapeutics, Inc.
- Immunomic Therapeutics
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Swartz, Adam M., Kendra L. Congdon, Smita K. Nair, Qi-Jing Li, James E. Herndon, Carter M. Suryadevara, Katherine A. Riccione, et al. “A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope.” Npj Vaccines 6, no. 1 (January 18, 2021): 12. https://doi.org/10.1038/s41541-020-00273-5.
    Full Text Open Access Copy Link to Item
  - Evgin, Laura, Amanda L. Huff, Phonphimon Wongthida, Jill Thompson, Tim Kottke, Jason Tonne, Matthew Schuelke, et al. “Oncolytic virus-derived type I interferon restricts CAR T cell therapy.” Nat Commun 11, no. 1 (June 24, 2020): 3187. https://doi.org/10.1038/s41467-020-17011-z.
    Full Text Link to Item
  - Gedeon, Patrick C., Michael A. Streicker, Teilo H. Schaller, Gary E. Archer, Micheal P. Jokinen, and John H. Sampson. “GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody.” Plos One 15, no. 7 (2020): e0236374. https://doi.org/10.1371/journal.pone.0236374.
    Full Text Link to Item
  - Suryadevara, Carter M., Rupen Desai, S Harrison Farber, Bryan D. Choi, Adam M. Swartz, Steven H. Shen, Patrick C. Gedeon, et al. “Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.” Clin Cancer Res 25, no. 1 (January 1, 2019): 358–68. https://doi.org/10.1158/1078-0432.CCR-18-1211.
    Full Text Link to Item
  - Atik, Ahmet F., Carter M. Suryadevara, Ryan M. Schweller, Jennifer L. West, Patrick Healy, James E. Herndon Ii, Kendra L. Congdon, et al. “Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells.” J Clin Neurosci 56 (October 2018): 163–68. https://doi.org/10.1016/j.jocn.2018.06.005.
    Full Text Link to Item
  - Cornetta, K., L. Duffy, S. A. Feldman, C. L. Mackall, M. L. Davila, K. J. Curran, R. P. Junghans, et al. “Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.” Molecular Therapy Methods and Clinical Development 10 (September 21, 2018): 371–78. https://doi.org/10.1016/j.omtm.2018.08.006.
    Full Text
  - Gedeon, Patrick C., Teilo H. Schaller, Satish K. Chitneni, Bryan D. Choi, Chien-Tsun Kuan, Carter M. Suryadevara, David J. Snyder, et al. “A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.” Clin Cancer Res 24, no. 15 (August 1, 2018): 3611–31. https://doi.org/10.1158/1078-0432.CCR-17-0126.
    Full Text Link to Item
  - Reap, Elizabeth A., Carter M. Suryadevara, Kristen A. Batich, Luis Sanchez-Perez, Gary E. Archer, Robert J. Schmittling, Pamela K. Norberg, et al. “Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.” Cancer Res 78, no. 1 (January 1, 2018): 256–64. https://doi.org/10.1158/0008-5472.CAN-17-0469.
    Full Text Link to Item
  - Suryadevara, Carter M., Rupen Desai, Melissa L. Abel, Katherine A. Riccione, Kristen A. Batich, Steven H. Shen, Pakawat Chongsathidkiet, et al. “Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.” Oncoimmunology 7, no. 6 (2018): e1434464. https://doi.org/10.1080/2162402X.2018.1434464.
    Full Text Open Access Copy Link to Item
  - Batich, Kristen A., Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, et al. “Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.” Clin Cancer Res 23, no. 8 (April 15, 2017): 1898–1909. https://doi.org/10.1158/1078-0432.CCR-16-2057.
    Full Text Link to Item
  - Saraswathula, Anirudh, Elizabeth A. Reap, Bryan D. Choi, Robert J. Schmittling, Pamela K. Norberg, Elias J. Sayour, James E. Herndon, et al. “Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.” Cancer Immunol Immunother 65, no. 2 (February 2016): 205–11. https://doi.org/10.1007/s00262-015-1784-3.
    Full Text Link to Item
  - Schuster, James, Rose K. Lai, Lawrence D. Recht, David A. Reardon, Nina A. Paleologos, Morris D. Groves, Maciej M. Mrugala, et al. “A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.” Neuro Oncol 17, no. 6 (June 2015): 854–61. https://doi.org/10.1093/neuonc/nou348.
    Full Text Link to Item
  - Mitchell, Duane A., Elias J. Sayour, Elizabeth Reap, Robert Schmittling, Gabriel DeLeon, Pamela Norberg, Annick Desjardins, et al. “Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.” Cancer Immunol Res 3, no. 4 (April 2015): 320–25. https://doi.org/10.1158/2326-6066.CIR-14-0100.
    Full Text Link to Item
  - Mitchell, Duane A., Kristen A. Batich, Michael D. Gunn, Min-Nung Huang, Luis Sanchez-Perez, Smita K. Nair, Kendra L. Congdon, et al. “Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.” Nature 519, no. 7543 (March 19, 2015): 366–69. https://doi.org/10.1038/nature14320.
    Full Text Open Access Copy Link to Item
  - Archer, G. E., E. Reap, P. Norberg, X. Cui, R. Schmittling, J. Herndon, V. Chandramohan, et al. “Idh1 mutations as a immunotherapeutic target for brain tumors.” Neuro Oncol 16 Suppl 3 (July 2014): iii40. https://doi.org/10.1093/neuonc/nou208.65.
    Full Text Link to Item
  - Nair, Smita K., Gabriel De Leon, David Boczkowski, Robert Schmittling, Weihua Xie, Janet Staats, Rebecca Liu, et al. “Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.” Clin Cancer Res 20, no. 10 (May 15, 2014): 2684–94. https://doi.org/10.1158/1078-0432.CCR-13-3268.
    Full Text Link to Item
  - Miao, Hongsheng, Bryan D. Choi, Carter M. Suryadevara, Luis Sanchez-Perez, Shicheng Yang, Gabriel De Leon, Elias J. Sayour, et al. “EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.” Plos One 9, no. 4 (2014): e94281. https://doi.org/10.1371/journal.pone.0094281.
    Full Text Open Access Copy Link to Item
  - Yang, Shicheng, Gary E. Archer, Catherine E. Flores, Duane A. Mitchell, and John H. Sampson. “A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.” Cancer Immunol Immunother 62, no. 11 (November 2013): 1649–62. https://doi.org/10.1007/s00262-013-1464-0.
    Full Text Link to Item
  - Choi, Bryan D., Patrick C. Gedeon, Chien-Tsun Kuan, Luis Sanchez-Perez, Gary E. Archer, Darell D. Bigner, and John H. Sampson. “Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.” J Immunol Methods 395, no. 1–2 (September 30, 2013): 14–20. https://doi.org/10.1016/j.jim.2013.06.003.
    Full Text Link to Item
  - Choi, Bryan D., Patrick C. Gedeon, James E. Herndon, Gary E. Archer, Elizabeth A. Reap, Luis Sanchez-Perez, Duane A. Mitchell, Darell D. Bigner, and John H. Sampson. “Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.” Cancer Immunol Res 1, no. 3 (September 2013): 163. https://doi.org/10.1158/2326-6066.CIR-13-0049.
    Full Text Link to Item
  - Dannull, Jens, N Rebecca Haley, Gary Archer, Smita Nair, David Boczkowski, Mark Harper, Nicole De Rosa, et al. “Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.” J Clin Invest 123, no. 7 (July 2013): 3135–45. https://doi.org/10.1172/JCI67544.
    Full Text Link to Item
  - Sanchez-Perez, Luis, Bryan D. Choi, Elizabeth A. Reap, Elias J. Sayour, Pamela Norberg, Robert J. Schmittling, Gerald E. Archer, et al. “BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.” Cancer Immunol Immunother 62, no. 6 (June 2013): 983–87. https://doi.org/10.1007/s00262-013-1405-y.
    Full Text Link to Item
  - Choi, Bryan D., Chien-Tsun Kuan, Mingqing Cai, Gary E. Archer, Duane A. Mitchell, Patrick C. Gedeon, Luis Sanchez-Perez, Ira Pastan, Darell D. Bigner, and John H. Sampson. “Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.” Proc Natl Acad Sci U S A 110, no. 1 (January 2, 2013): 270–75. https://doi.org/10.1073/pnas.1219817110.
    Full Text Link to Item
  - Sanchez-Perez, Luis A., Bryan D. Choi, Gary E. Archer, Xiuyu Cui, Catherine Flores, Laura A. Johnson, Robert J. Schmittling, et al. “Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.” Plos One 8, no. 3 (2013): e59082. https://doi.org/10.1371/journal.pone.0059082.
    Full Text Open Access Copy Link to Item
  - Nair, Smita, Gerald E. Archer, and Thomas F. Tedder. “Isolation and generation of human dendritic cells.” Curr Protoc Immunol Chapter 7 (November 2012): 7.32.1-7.32.23. https://doi.org/10.1002/0471142735.im0732s99.
    Full Text Link to Item
  - Sampson, John H., Robert J. Schmittling, Gary E. Archer, Kendra L. Congdon, Smita K. Nair, Elizabeth A. Reap, Annick Desjardins, et al. “A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.” Plos One 7, no. 2 (2012): e31046. https://doi.org/10.1371/journal.pone.0031046.
    Full Text Open Access Copy Link to Item
  - Mitchell, Duane A., Gary E. Archer, Henry S. Friedman, James E. Herndon, Darell D. Bigner, and John H. Sampson. “DENDRITIC CELL VACCINES TARGETING CYTOMEGALOVIRUS IN GLIOBLASTOMA.” Neuro Oncology 13 (November 1, 2011): 39–39.
    Link to Item
  - Mitchell, Duane A., Xiuyu Cui, Robert J. Schmittling, Luis Sanchez-Perez, David J. Snyder, Kendra L. Congdon, Gary E. Archer, et al. “Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.” Blood 118, no. 11 (September 15, 2011): 3003–12. https://doi.org/10.1182/blood-2011-02-334565.
    Full Text Link to Item
  - Mehta, A. I., O. Persson, J. E. Herndon, G. E. Archer, R. McLendon, A. B. Heimberger, D. A. Mitchell, D. D. Bigner, and J. H. Sampson. “Reply to M.S. Lesniak.” Journal of Clinical Oncology 29, no. 22 (August 1, 2011): 3105–6. https://doi.org/10.1200/JCO.2011.35.0256.
    Full Text
  - Sampson, John H., Kenneth D. Aldape, Gary E. Archer, April Coan, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, et al. “Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.” Neuro Oncol 13, no. 3 (March 2011): 324–33. https://doi.org/10.1093/neuonc/noq157.
    Full Text Link to Item
  - Sampson, John H., Amy B. Heimberger, Gary E. Archer, Kenneth D. Aldape, Allan H. Friedman, Henry S. Friedman, Mark R. Gilbert, et al. “Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.” J Clin Oncol 28, no. 31 (November 1, 2010): 4722–29. https://doi.org/10.1200/JCO.2010.28.6963.
    Full Text Link to Item
  - Sampson, John H., Gary Archer, Christoph Pedain, Eva Wembacher-Schröder, Manfred Westphal, Sandeep Kunwar, Michael A. Vogelbaum, et al. “Poor drug distribution as a possible explanation for the results of the PRECISE trial.” J Neurosurg 113, no. 2 (August 2010): 301–9. https://doi.org/10.3171/2009.11.JNS091052.
    Full Text Link to Item
  - Choi, Bryan D., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, Roger E. McLendon, Darell D. Bigner, and John H. Sampson. “EGFRvIII-targeted vaccination therapy of malignant glioma.” Brain Pathol 19, no. 4 (October 2009): 713–23. https://doi.org/10.1111/j.1750-3639.2009.00318.x.
    Full Text Link to Item
  - Sampson, John H., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, James E. Herndon, Denise Lally-Goss, Sharon McGehee-Norman, et al. “An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.” Mol Cancer Ther 8, no. 10 (October 2009): 2773–79. https://doi.org/10.1158/1535-7163.MCT-09-0124.
    Full Text Link to Item
  - Heimberger, A. B., G. E. Archer, D. A. Mitchell, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, et al. “Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2021.
    Link to Item
  - Sampson, J. H., G. E. Archer, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, H. S. Friedman, T. Keler, D. A. Reardon, and D. A. Mitchell. “Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2034.
    Link to Item
  - Archer, Gary E., Amy B. Heimberger, Darell D. Bigner, Tom Davis, Henry S. Friedman, Tibor Keler, Roger E. McLendon, et al. “INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRVIII-TARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED EGFRVIII-POSITIVE GBM.” Neuro Oncology 11, no. 2 (April 1, 2009): 224–224.
    Link to Item
  - Heimberger, Amy B., Ling-Yuan Kong, Mohamed Abou-Ghazal, Chantal Reina-Ortiz, David S. Yang, Jun Wei, Wei Qiao, et al. “The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.” Clin Neurosurg 56 (2009): 98–106.
    Link to Item
  - Schmittling, Robert J., Gary E. Archer, Duane A. Mitchell, Amy Heimberger, Charles Pegram, James E. Herndon, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.” J Immunol Methods 339, no. 1 (November 30, 2008): 74–81. https://doi.org/10.1016/j.jim.2008.08.004.
    Full Text Link to Item
  - Sampson, John H., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, and Darell D. Bigner. “Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.” Semin Immunol 20, no. 5 (October 2008): 267–75. https://doi.org/10.1016/j.smim.2008.04.001.
    Full Text Link to Item
  - Kong, Ling-Yuan, Mohamed K. Abou-Ghazal, Jun Wei, Arup Chakraborty, Wei Sun, Wei Qiao, Gregory N. Fuller, et al. “A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.” Clin Cancer Res 14, no. 18 (September 15, 2008): 5759–68. https://doi.org/10.1158/1078-0432.CCR-08-0377.
    Full Text Link to Item
  - Sampson, John H., Gamal Akabani, Gerald E. Archer, Mitchel S. Berger, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, et al. “Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.” Neuro Oncol 10, no. 3 (June 2008): 320–29. https://doi.org/10.1215/15228517-2008-012.
    Full Text Link to Item
  - Mitchell, D., G. E. Archer, D. D. Bigner, H. S. Friedman, D. Lally-Goss, J. E. Herndon, S. McGehee, R. McLendon, D. A. Reardon, and J. H. Sampson. “Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM.” Journal of Clinical Oncology 26, no. 15 (May 20, 2008).
    Link to Item
  - Sampson, J. H., G. E. Archer, D. D. Bigner, T. Davis, H. S. Friedman, T. Keler, D. A. Mitchell, D. A. Reardon, R. Sawaya, and A. B. Heimberger. “Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2011–2011. https://doi.org/10.1200/jco.2008.26.15_suppl.2011.
    Full Text
  - Heimberger, Amy B., Wei Sun, S Farzana Hussain, Mahua Dey, Lamonne Crutcher, Ken Aldape, Mark Gilbert, et al. “Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.” Neuro Oncol 10, no. 1 (February 2008): 98–103. https://doi.org/10.1215/15228517-2007-046.
    Full Text Link to Item
  - Ochiai, Hidenobu, Gary E. Archer, James E. Herndon, Chien-Tsun Kuan, Duane A. Mitchell, Darell D. Bigner, Ira H. Pastan, and John H. Sampson. “EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.” Cancer Immunol Immunother 57, no. 1 (January 2008): 115–21. https://doi.org/10.1007/s00262-007-0363-7.
    Full Text Link to Item
  - Fecci, Peter E., Hidenobu Ochiai, Duane A. Mitchell, Peter M. Grossi, Alison E. Sweeney, Gary E. Archer, Thomas Cummings, James P. Allison, Darell D. Bigner, and John H. Sampson. “Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.” Clin Cancer Res 13, no. 7 (April 1, 2007): 2158–67. https://doi.org/10.1158/1078-0432.CCR-06-2070.
    Full Text Link to Item
  - Learn, Chris A., Peter E. Fecci, Robert J. Schmittling, Weihua Xie, Isaac Karikari, Duane A. Mitchell, Gary E. Archer, ZhengZheng Wei, Holly Dressman, and John H. Sampson. “Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers.” Clin Cancer Res 12, no. 24 (December 15, 2006): 7306–15. https://doi.org/10.1158/1078-0432.CCR-06-1727.
    Full Text Link to Item
  - Ochiai, Hidenobu, Chris T. Pernell, Gary E. Archer, Tracy A. Chewning, Roger E. McLendon, Henry S. Friedman, and John H. Sampson. “Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.” Neurol Med Chir (Tokyo) 46, no. 10 (October 2006): 485–89. https://doi.org/10.2176/nmc.46.485.
    Full Text Link to Item
  - Leon, A. C., C. H. Mallinckrodt, C. Chuang Stein, D. G. Archibald, G. E. Archer, and K. Chartier. “Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology.” Biological Psychiatry 59, no. 11 (June 2006): 1001–5.
  - Fecci, Peter E., Duane A. Mitchell, John F. Whitesides, Weihua Xie, Allan H. Friedman, Gary E. Archer, James E. Herndon, Darell D. Bigner, Glenn Dranoff, and John H. Sampson. “Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.” Cancer Res 66, no. 6 (March 15, 2006): 3294–3302. https://doi.org/10.1158/0008-5472.CAN-05-3773.
    Full Text Link to Item
  - Ochiai, Hidenobu, Stephanie A. Campbell, Gary E. Archer, Tracy A. Chewning, Eugenia Dragunsky, Alexander Ivanov, Matthias Gromeier, and John H. Sampson. “Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus.” Clin Cancer Res 12, no. 4 (February 15, 2006): 1349–54. https://doi.org/10.1158/1078-0432.CCR-05-1595.
    Full Text Link to Item
  - Ochiai, Hidenobu, Stephanie A. Moore, Gary E. Archer, Tatsunori Okamura, Tracy A. Chewning, Jeffrey R. Marks, John H. Sampson, and Matthias Gromeier. “Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus.” Clin Cancer Res 10, no. 14 (July 15, 2004): 4831–38. https://doi.org/10.1158/1078-0432.CCR-03-0694.
    Full Text Link to Item
  - Learn, Chris A., Tristan L. Hartzell, Carol J. Wikstrand, Gary E. Archer, Jeremy N. Rich, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.” Clin Cancer Res 10, no. 9 (May 1, 2004): 3216–24. https://doi.org/10.1158/1078-0432.ccr-03-0521.
    Full Text Link to Item
  - Grossi, Peter M., Hidenobu Ochiai, Gary E. Archer, Roger E. McLendon, Michael R. Zalutsky, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.” Clin Cancer Res 9, no. 15 (November 15, 2003): 5514–20.
    Link to Item
  - Sampson, John H., Gamal Akabani, Gary E. Archer, Darell D. Bigner, Mitchel S. Berger, Allan H. Friedman, Henry S. Friedman, et al. “Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.” J Neurooncol 65, no. 1 (October 2003): 27–35. https://doi.org/10.1023/a:1026290315809.
    Full Text Link to Item
  - Heimberger, Amy B., Laura E. Crotty, Gary E. Archer, Kenneth R. Hess, Carol J. Wikstrand, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.” Clin Cancer Res 9, no. 11 (September 15, 2003): 4247–54.
    Link to Item
  - Fecci, Peter E., Duane A. Mitchell, Gary E. Archer, Michael A. Morse, H Kim Lyerly, Darell D. Bigner, and John H. Sampson. “The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.” J Neurooncol 64, no. 1–2 (2003): 161–76. https://doi.org/10.1007/BF02700031.
    Full Text Link to Item
  - Heimberger, Amy B., Chris A. Learn, Gary E. Archer, Roger E. McLendon, Tracy A. Chewning, Frank L. Tuck, John B. Pracyk, et al. “Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).” Clin Cancer Res 8, no. 11 (November 2002): 3496–3502.
    Link to Item
  - Lal, Anita, Chad A. Glazer, Holly M. Martinson, Henry S. Friedman, Gary E. Archer, John H. Sampson, and Gregory J. Riggins. “Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.” Cancer Res 62, no. 12 (June 15, 2002): 3335–39.
    Link to Item
  - Heimberger, Amy B., Gary E. Archer, Laura E. Crotty, Roger E. McLendon, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.” Neurosurgery 50, no. 1 (January 2002): 158–64. https://doi.org/10.1097/00006123-200201000-00024.
    Full Text Link to Item
  - Tedder, Thomas F., and Paul J. Jansen. “Isolation and generation of human dendritic cells.” Curr Protoc Immunol Chapter 7 (May 2001): 7.32.1-7.32.16. https://doi.org/10.1002/0471142735.im0732s23.
    Full Text Link to Item
  - Wildsmith, S. E., G. E. Archer, A. J. Winkley, P. W. Lane, and P. J. Bugelski. “Maximization of signal derived from cDNA microarrays.” Biotechniques 30, no. 1 (January 2001): 202–8. https://doi.org/10.2144/01301dd04.
    Full Text Link to Item
  - Kuan, C. T., C. J. Wikstrand, G. Archer, R. Beers, I. Pastan, M. R. Zalutsky, and D. D. Bigner. “Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.” Int J Cancer 88, no. 6 (December 15, 2000): 962–69. https://doi.org/10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u.
    Full Text Link to Item
  - Heimberger, A. B., G. E. Archer, R. E. McLendon, D. Price, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson. “Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.” Clinical Cancer Research 6 (November 1, 2000): 4542S-4543S.
    Link to Item
  - Heimberger, A. B., G. E. Archer, R. E. McLendon, C. Hulette, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson. “Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.” Clin Cancer Res 6, no. 10 (October 2000): 4148–53.
    Link to Item
  - Sampson, J. H., L. E. Crotty, S. Lee, G. E. Archer, D. M. Ashley, C. J. Wikstrand, L. P. Hale, et al. “Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.” Proc Natl Acad Sci U S A 97, no. 13 (June 20, 2000): 7503–8. https://doi.org/10.1073/pnas.130166597.
    Full Text Link to Item
  - Heimberger, A. B., L. E. Crotty, G. E. Archer, R. E. McLendon, A. Friedman, G. Dranoff, D. D. Bigner, and J. H. Sampson. “Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma.” J Neuroimmunol 103, no. 1 (February 1, 2000): 16–25. https://doi.org/10.1016/s0165-5728(99)00172-1.
    Full Text Link to Item
  - Archer, G. E., J. H. Sampson, I. A. Lorimer, R. E. McLendon, C. T. Kuan, A. H. Friedman, H. S. Friedman, I. H. Pastan, and D. D. Bigner. “Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.” Clin Cancer Res 5, no. 9 (September 1999): 2646–52.
    Link to Item
  - McLendon, R. E., G. E. Archer, R. H. Larsen, G. Akabani, D. D. Bigner, and M. R. Zalutsky. “Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.” Int J Radiat Oncol Biol Phys 45, no. 2 (September 1, 1999): 491–99. https://doi.org/10.1016/s0360-3016(99)00206-0.
    Full Text Link to Item
  - Kuan, C. T., C. J. Reist, C. F. Foulon, I. A. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner. “125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.” Clin Cancer Res 5, no. 6 (June 1999): 1539–49.
    Link to Item
  - Sampson, J. H., G. E. Archer, A. T. Villavicencio, R. E. McLendon, A. H. Friedman, W. R. Bishop, D. D. Bigner, and H. S. Friedman. “Treatment of neoplastic meningitis with intrathecal temozolomide.” Clin Cancer Res 5, no. 5 (May 1999): 1183–88.
    Link to Item
  - Kuan, C. T., C. J. Reist, C. F. Foulon, I. A. J. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner. “¹²⁵I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.” Clinical Cancer Research 5, no. 6 (1999): 1539–49.
  - Smith, C. C., G. E. Archer, E. J. Forster, T. R. Lambert, R. W. Rees, and A. M. Lynch. “Analysis of gene mutations and clastogenicity following short-term treatment with azathioprine in MutaMouse.” Environ Mol Mutagen 34, no. 2–3 (1999): 131–39.
    Link to Item
  - Archer, G. E., J. H. Sampson, R. E. McLendon, A. H. Friedman, O. M. Colvin, M. Rose, H. Sands, et al. “Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.” J Neurooncol 44, no. 3 (1999): 233–41. https://doi.org/10.1023/a:1006304424346.
    Full Text Link to Item
  - Ashley, D. M., J. H. Sampson, G. E. Archer, L. P. Hale, and D. D. Bigner. “Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model.” J Neuroimmunol 86, no. 1 (June 1, 1998): 46–52. https://doi.org/10.1016/s0165-5728(98)00017-4.
    Full Text Link to Item
  - Wikstrand, C. J., C. J. Reist, G. E. Archer, M. R. Zalutsky, and D. D. Bigner. “The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.” J Neurovirol 4, no. 2 (April 1998): 148–58. https://doi.org/10.3109/13550289809114515.
    Full Text Link to Item
  - Sampson, J. H., D. M. Ashley, G. E. Archer, H. E. Fuchs, G. Dranoff, L. P. Hale, and D. D. Bigner. “Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion.” Neurosurgery 41, no. 6 (December 1997): 1365–72. https://doi.org/10.1097/00006123-199712000-00024.
    Full Text Link to Item
  - Ashley, D. M., J. H. Sampson, G. E. Archer, S. K. Batra, D. D. Bigner, and L. P. Hale. “A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.” J Neuroimmunol 78, no. 1–2 (September 1997): 34–46. https://doi.org/10.1016/s0165-5728(97)00080-5.
    Full Text Link to Item
  - Archer, G. E., J. H. Sampson, and D. D. Bigner. “Viruses and oncogenes in brain tumors.” J Neurovirol 3 Suppl 1 (May 1997): S76–77.
    Link to Item
  - Reist, C. J., G. E. Archer, C. J. Wikstrand, D. D. Bigner, and M. R. Zalutsky. “Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.” Cancer Res 57, no. 8 (April 15, 1997): 1510–15.
    Link to Item
  - Bean, J. M., G. E. Archer, M. T. Munley, E. Ong, S. A. Snyder, Z. A. Haroon, R. E. McLendon, et al. “2013 The impact of hypoxia and oxygenation modification on the radiation response of an intracranial rat glioma.” International Journal of Radiation Oncology*Biology*Physics 39, no. 2 (January 1997): 247–247. https://doi.org/10.1016/s0360-3016(97)80782-1.
    Full Text
  - Kurpad, S. N., M. E. Dolan, R. E. McLendon, G. E. Archer, R. C. Moschel, A. E. Pegg, D. D. Bigner, and H. S. Friedman. “Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.” Cancer Chemother Pharmacol 39, no. 4 (1997): 307–16. https://doi.org/10.1007/s002800050577.
    Full Text Link to Item
  - Sampson, J. H., G. E. Archer, D. M. Ashley, H. E. Fuchs, L. P. Hale, G. Dranoff, and D. D. Bigner. “Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.” Proc Natl Acad Sci U S A 93, no. 19 (September 17, 1996): 10399–404. https://doi.org/10.1073/pnas.93.19.10399.
    Full Text Link to Item
  - Zalutsky, M. R., G. E. Archer, P. K. Garg, S. K. Batra, and D. D. Bigner. “Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.” Nucl Med Biol 23, no. 4 (May 1996): 449–58. https://doi.org/10.1016/0969-8051(96)00021-2.
    Full Text Link to Item
  - McLendon, R. E., G. E. Archer, P. K. Garg, D. D. Bigner, and M. R. Zalutsky. “Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis.” Int J Radiat Oncol Biol Phys 35, no. 1 (April 1, 1996): 69–80. https://doi.org/10.1016/s0360-3016(96)85013-9.
    Full Text Link to Item
  - Zalutsky, M. R., J. M. Schuster, P. K. Garg, G. E. Archer, M. W. Dewhirst, and D. D. Bigner. “Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.” Recent Results Cancer Res 141 (1996): 101–22. https://doi.org/10.1007/978-3-642-79952-5_7.
    Full Text Link to Item
  - Bigner, D. D., G. E. Archer, R. E. McLendon, H. S. Friedman, H. E. Fuchs, L. H. Pai, J. E. Herndon, and I. H. Pastan. “Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.” Clin Cancer Res 1, no. 12 (December 1995): 1545–55.
    Link to Item
  - Reist, C. J., G. E. Archer, S. N. Kurpad, C. J. Wikstrand, G. Vaidyanathan, M. C. Willingham, D. K. Moscatello, A. J. Wong, D. D. Bigner, and M. R. Zalutsky. “Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.” Cancer Res 55, no. 19 (October 1, 1995): 4375–82.
    Link to Item
  - Kurpad, S. N., H. S. Friedman, G. E. Archer, R. E. McLendon, W. M. Petros, H. E. Fuchs, A. Guaspari, and D. D. Bigner. “Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats.” Cancer Res 55, no. 17 (September 1, 1995): 3803–9.
    Link to Item
  - Pastan, I. H., G. E. Archer, R. E. McLendon, H. S. Friedman, H. E. Fuchs, Q. C. Wang, L. H. Pai, J. Herndon, and D. D. Bigner. “Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.” Proc Natl Acad Sci U S A 92, no. 7 (March 28, 1995): 2765–69. https://doi.org/10.1073/pnas.92.7.2765.
    Full Text Link to Item
  - Friedman, H. S., G. E. Archer, R. E. McLendon, J. M. Schuster, O. M. Colvin, A. Guaspari, R. Blum, P. A. Savina, H. E. Fuchs, and D. D. Bigner. “Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats.” Cancer Res 54, no. 17 (September 1, 1994): 4710–14.
    Link to Item
  - Page, R. L., P. K. Garg, S. Garg, G. E. Archer, O. S. Bruland, and M. R. Zalutsky. “PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment.” J Nucl Med 35, no. 9 (September 1994): 1506–13.
    Link to Item
  - Zalutsky, M. R., R. E. McLendon, P. K. Garg, G. E. Archer, J. M. Schuster, and D. D. Bigner. “Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.” Cancer Res 54, no. 17 (September 1, 1994): 4719–25.
    Link to Item
  - He, X., G. E. Archer, C. J. Wikstrand, S. L. Morrison, M. R. Zalutsky, D. D. Bigner, and S. K. Batra. “Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin.” J Neuroimmunol 52, no. 2 (July 1994): 127–37. https://doi.org/10.1016/0165-5728(94)90106-6.
    Full Text Link to Item
  - Friedman, H. S., G. Archer, and D. D. Bigner. “Re: Toxicity of intrathecal melphalan.” J Natl Cancer Inst 86, no. 11 (June 1, 1994): 870–71. https://doi.org/10.1093/jnci/86.11.870.
    Full Text Link to Item
  - Wikstrand, C. J., S. D. Stanley, P. A. Humphrey, C. N. Pegram, G. E. Archer, S. Kurpad, M. Shibuya, and D. D. Bigner. “Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas.” J Neuroimmunol 46, no. 1–2 (July 1993): 165–73. https://doi.org/10.1016/0165-5728(93)90246-u.
    Full Text Link to Item
  - Schuster, J. M., H. S. Friedman, G. E. Archer, H. E. Fuchs, R. E. McLendon, O. M. Colvin, and D. D. Bigner. “Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.” Cancer Res 53, no. 10 Suppl (May 15, 1993): 2338–43.
    Link to Item
  - Schuster, J. M., H. S. Friedman, G. E. Archer, H. E. Fuchs, R. E. McLendon, and D. D. Bigner. “Intraarterial Therapy of Human Glioma Xenografts in Athymic Rats Using 4-Hydroperoxycyclophosphamide.” Cancer Research 53, no. 10 (January 1, 1993): 2338–43.
  - Humphrey, P. A., L. M. Gangarosa, A. J. Wong, G. E. Archer, M. Lund-Johansen, R. Bjerkvig, O. D. Laerum, H. S. Friedman, and D. D. Bigner. “Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.” Biochem Biophys Res Commun 178, no. 3 (August 15, 1991): 1413–20. https://doi.org/10.1016/0006-291x(91)91051-d.
    Full Text Link to Item
  - Humphrey, P. A., A. J. Wong, B. Vogelstein, M. R. Zalutsky, G. N. Fuller, G. E. Archer, H. S. Friedman, M. M. Kwatra, S. H. Bigner, and D. D. Bigner. “Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.” Proc Natl Acad Sci U S A 87, no. 11 (June 1990): 4207–11. https://doi.org/10.1073/pnas.87.11.4207.
    Full Text Link to Item
  - Fuchs, H. E., G. E. Archer, O. M. Colvin, S. H. Bigner, J. M. Schuster, G. N. Fuller, L. H. Muhlbaier, S. C. Schold, H. S. Friedman, and D. D. Bigner. “Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis.” Cancer Res 50, no. 6 (March 15, 1990): 1954–59.
    Link to Item
  - Colapinto, E. V., M. R. Zalutsky, G. E. Archer, M. A. Noska, H. S. Friedman, S. Carrel, and D. D. Bigner. “Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.” Cancer Res 50, no. 6 (March 15, 1990): 1822–27.
    Link to Item
  - Garg, P. K., G. E. Archer, D. D. Bigner, and M. R. Zalutsky. “Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling.” Int J Rad Appl Instrum A 40, no. 6 (1989): 485–90. https://doi.org/10.1016/0883-2889(89)90131-7.
    Full Text Link to Item
  - Archer, G. E., and L. A. Furlong. “Acute abdomen caused by placenta percreta in the second trimester.” Am J Obstet Gynecol 157, no. 1 (July 1987): 146–47. https://doi.org/10.1016/s0002-9378(87)80367-8.
    Full Text Link to Item
  - Dhib-Jalbut, S., G. E. Archer, and B. H. Liwnicz. “Immunocytochemical binding to neurons of serum from spinocerebellar degeneration patients.” J Child Neurol 1, no. 3 (July 1986): 198–205. https://doi.org/10.1177/088307388600100304.
    Full Text Link to Item
  - Liwnicz, B. H., G. Archer, S. W. Soukup, and R. G. Liwnicz. “Continuous human glioma-derived cell lines UC-11MG and UC-302MG. Morphologic, immunocytochemical and chromosomal characterization.” J Neurooncol 3, no. 4 (1986): 373–85. https://doi.org/10.1007/BF00165588.
    Full Text Link to Item
  - Liwnicz, B. H., and G. Archer. “RG2, a clone of nitrosourea-induced rat glioma, can be used for studying astrocytic differentiation in vitro.” Journal of Neuropathology and Experimental Neurology 41, no. 3 (January 1, 1982). https://doi.org/10.1097/00005072-198205000-00091.
    Full Text
  - ARCHER, G. E. “Suppurative labyrinthitis.” Proceedings of the Royal Society of Medicine, Not Available 45, no. 3 (March 1952): 121–27.
- Conference Papers
  - Peters, Katherine B., Gerald E. Archer, Pamela Norberg, Weihua Xie, Stevie Threatt, Eric S. Lipp, James Emmett Herndon, et al. “Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.” In Journal of Clinical Oncology, 37:e13526–e13526. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e13526.
    Full Text
  - Dunn-Pirio, Anastasie, Katherine Peters, Dina Randazzo, Hentry Friedman, Patrick Healy, James Herndon, Elizabeth Reap, et al. “Tumor stem cell RNA-leaded dedritic cell vaccine for recurrent glioblastoma: a phase 1 trail.” In Neurology, 88:S41–S41. American Academy of Neurology, 2017.
    Link to Item
  - Gedeon, Patrick C., Teilo H. Schaller, Carter M. Suryadevara, Bryan D. Choi, Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Darell D. Bigner, and John H. Sampson. “A FULLY-HUMAN EGFRvIII-TARGETED BISPECIFIC ANTIBODY REDIRECTS HUMAN T CELLS TO SPECIFICALLY LYSE MALIGNANT GLIOMA.” In Neuro Oncology, 18:96–96. OXFORD UNIV PRESS INC, 2016.
    Link to Item
  - Vlahovic, Gordana, Gerald E. Archer, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, Patrick Healy, et al. “Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 34:e13518–e13518. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e13518.
    Full Text Link to Item
  - Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, et al. “Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 33:e13030–e13030. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e13030.
    Full Text
  - Sampson, J., D. A. Mitchell, K. A. Batich, D. Snyder, W. Xie, E. Reap, X. Cui, et al. “RANDOMIZATION OF PATIENTS WITH GLIOBLASTOMA TO VACCINE SITE PRE-CONDITIONING WITH TETANUS-DIPHTHERIA TOXOID SYSTEMICALLY ENHANCES MIGRATION AND THERAPEUTIC EFFECT OF CYTOMEGALOVIRUS PP65-PULSED DENDRITIC CELL VACCINE IN A MIP-1α-DEPENDENT FASHION.” In Neuro Oncol, 16 Suppl 3:iii39–40, 2014. https://doi.org/10.1093/neuonc/nou208.63.
    Full Text Link to Item
  - Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Sharon Norman, Annick Desjardins, Katherine B. Peters, Tulika Ranjan, et al. “Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 32:3069–3069. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.3069.
    Full Text
  - Archer, Gary E., Weihua Xie, Pamela Norberg, Anjelika Dechkovskaia, Allan Friedman, Darell D. Bigner, Duane A. Mitchell, John H. Sampson, and David Boczkowski. “FEASIBILITY OF AMPLIFIED CD133((+)) BRAIN TUMOR STEM CELL RNA-PULSED DENDRITIC CELLS FOR THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 14:49–49. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Yang, Shicheng, Gary E. Archer, Hongsheng Miao, Xiuyu Cui, Weihua Xie, David Snyder, Andrea J. Pretorian, et al. “EX VIVO GENERATION OF CENTRAL MEMORY-LIKE ANTI-TUMOR T CELLS TO TREAT MALIGNANT BRAIN TUMORS.” In Neuro Oncology, 14:45–45. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Johnson, Laura A., Gary E. Archer, Smita K. Nair, Robert Schmittling, Elizabeth Reap, and John H. Sampson. “CYTOMEGALOVIRUS-SPECIFIC IMMUNE DEFICITS IN PATIENTS WITH GBM.” In Neuro Oncology, 13:39–39. OXFORD UNIV PRESS INC, 2011.
    Link to Item
  - Heimberger, A. B., G. E. Archer, D. A. Mitchell, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, et al. “Epidermal growth factor receptor variant III (EGFRvIII) vaccine ( CDX-110) in GBM.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Sampson, J. H., G. E. Archer, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, H. S. Friedman, T. Keler, D. A. Reardon, and D. A. Mitchell. “Effect of daclizumab on T-Reg counts and EGFRvIII-specific immune responses in GBM.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Mitchell, Duane A., Gary E. Archer, Darell D. Bigner, Henry S. Friedman, Denise Lally-Goss, Beth Perry, James E. Herndon, et al. “RNA Transfected Dendritic Cell Vaccines Targeting Human Cytomegalovirus Antigens in Patients with Glioblastoma.” In Molecular Therapy, 17:S93–S93. NATURE PUBLISHING GROUP, 2009.
    Link to Item
  - Sampson, J. H., K. D. Aldape, M. R. Gilbert, S. J. Hassenbusch, R. Sawaya, B. Schmittling, G. E. Archer, et al. “Temozolomide as a vaccine adjuvant in GBM.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Learn, C. A., R. J. Schmittling, P. E. Fecci, D. A. Mitchell, G. E. Archer, and J. H. Sampson. “Expression profiling of CD4+ and CD8+ T cells in malignant glioma.” In Clinical Cancer Research, 11:8999S-8999S. AMER ASSOC CANCER RESEARCH, 2005.
    Link to Item
  - Archer, G. E., D. Bigner, A. Friedman, H. Friedman, K. Penne, D. Lally-Batts, A. Paolino, S. Tourt-Uhlig, D. Reardon, and J. Sampson. “Dendritic cell vaccine for intracranial tumors I (DC Victori trial).” In Neuro Oncology, 6:341–341. DUKE UNIV PRESS, 2004.
    Link to Item
  - Boskovitz, A., G. Vaidyanathan, G. E. Archer, H. Ochiai, T. Okamura, J. H. Sampson, D. D. Bigner, and M. R. Zalutsky. “Medulloblastoma neoplastic meningitis targeted radiotherapy with intrathecal alpha-emitter At-211-labeled thymidine analogue.” In Neuro Oncology, 6:403–403. DUKE UNIV PRESS, 2004.
    Link to Item
  - Archer, G. E., J. M. Schuster, H. E. Fuchs, A. Guaspari, D. P. Bigner, H. S. Friedman, and R. E. McLendon. “NEUROPATHOLOGY OF MULTIPLE VERSUS SINGLE DOSE INTRATHECAL MELPHALAN IN RATS.” In Journal of Neuropathology and Experimental Neurology, 52:298–298. Oxford University Press (OUP), 1993. https://doi.org/10.1097/00005072-199305000-00152.
    Full Text
  - Fuchs, H. E., G. E. Archer, J. M. Schuster, O. M. Colvin, S. H. Bigner, L. H. Muhlbaier, H. S. Friedman, and D. D. Bigner. “A NUDE RAT MODEL OF LEPTOMENINGEAL TUMOR DISSEMINATION (LTD) OF HUMAN MEDULLOBLASTOMA.” In Journal of Neuropathology and Experimental Neurology, 48:356–356. Oxford University Press (OUP), 1989. https://doi.org/10.1097/00005072-198905000-00173.
    Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

Selected Grants

External Relationships

Selected Publications

Academic Articles

Conference Papers